-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 OzjZ5XJmJrnuZ85Qxqu2oM/gxvFyCB12upmCwmC3gmEBZ1CaQHQLaZV364kueKbQ
 MmE5pH+/Gf2d1t0TWuDY9Q==

<SEC-DOCUMENT>0001010549-06-000635.txt : 20060921
<SEC-HEADER>0001010549-06-000635.hdr.sgml : 20060921
<ACCEPTANCE-DATETIME>20060921164652
ACCESSION NUMBER:		0001010549-06-000635
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20060906
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20060921
DATE AS OF CHANGE:		20060921

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CHINA PHARMA HOLDINGS, INC.
		CENTRAL INDEX KEY:			0001106644
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				731564807
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29523
		FILM NUMBER:		061102527

	BUSINESS ADDRESS:	
		STREET 1:		2ND FLOOR, NO. 17, JINPAN ROAD
		STREET 2:		HAIKOU
		CITY:			HAINAN PROVINCE
		STATE:			F4
		ZIP:			570216
		BUSINESS PHONE:		8689866811730

	MAIL ADDRESS:	
		STREET 1:		2ND FLOOR, NO. 17, JINPAN ROAD
		STREET 2:		HAIKOU
		CITY:			HAINAN PROVINCE
		STATE:			F4
		ZIP:			570216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TS ELECTRONICS INC
		DATE OF NAME CHANGE:	20030818

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SOFTSTONE INC
		DATE OF NAME CHANGE:	20030128

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SOFTSTONE INC /DE/
		DATE OF NAME CHANGE:	20010808
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cph8k090606.txt
<TEXT>

- --------------------------------------------------------------------------------

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington D.C. 20549

                                    FORM 8-K
                                 CURRENT REPORT


   PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934

       Date of Report (Date of Earliest Event Reported): September 21, 2006

                           China Pharma Holdings, Inc.
- --------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

        Delaware                    000-29523                   73-1564807
- --------------------------------------------------------------------------------
(State of Incorporation)      (Commission File No.)        (IRS Employer ID No.)

                         2nd Floor, No. 17, Jinpan Road
                         Haikou, Hainan Province, China
                    (Address of Principal Executive Offices)

                                 86-898-66811730
               Registrant's Telephone Number, Including Area Code:


Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[_]  Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR.425)

[_]  Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[_]  Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b))

[_]  Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-4(c))


- --------------------------------------------------------------------------------

Item 2.02.  Results of Operations and Financial Condition

China Pharma Holdings, Inc. issued a press release on September 20, 2006. A copy
of the press release is attached hereto as Exhibit 99.1.

<PAGE>

The information in this Current Report included in this Item 2.02, including the
exhibit included  herewith,  is furnished pursuant to Item 2.02 and shall not be
deemed to be filed for purposes of Section 18 of the Exchange  Act, or otherwise
subject to the liabilities of that section.

Item 9.01.  Financial Statements and Exhibits

Exhibits

     99.1   Press release issued by the Company dated September 20, 2006.


- --------------------------------------------------------------------------------


                                   SIGNATURES


Pursuant to the  requirements  of the  Securities  and Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


China Pharma Holdings, Inc.


Date: September 21, 2006


/s/  Zhilin Li
- -----------------------
     Zhilin Li
     President and CEO
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>cph8kex991090606.txt
<DESCRIPTION>PRESS RELEASE DATED AUGUST 15, 2006
<TEXT>

Contact:

Crocker Coulson                               Donald Xu
President                                     Vice President, Strategic Planning
CCG Elite                                     China Pharma Holdings, Inc.
310 231-8600 ext 103                          858-776-8880
crocker.coulson@ccgir.com                     dxu@chinapharmaholdings.com

FOR IMMEDIATE RELEASE

                           China Pharma Holdings, Inc.
                        Provides Preliminary 2007 Outlook

HAIKOU CITY, Hainan Province,  PRC - September 20, 2006 - China Pharma Holdings,
Inc. ("China Pharma") (OTC BB: CPHI.OB) today provided a preliminary outlook for
its 2007 financial results.

The  Company  previously  announced  that it expects to achieve  revenues of $20
million and net income of $8 million for the year ending  December 31, 2006. The
Company  expects  net  income  to  increase  by at least  30% for 2007 from 2006
levels.  This  guidance  is based on recent  new drug  introductions  and strong
pipeline development.

"China Pharma's  strategy of growth through  aggressive new product launches and
strong  research and  development  provides us  confidence  that we will sustain
improved net income for 2007. Recent product launches include  Propylgallate and
Ozagrel, which treat cardiovascular & cerebrovascular  conditions, the first and
third  leading  causes of death in China,  respectively,"  commented Li Zhi Lin,
President and CEO.

About China Pharma Holdings, Inc.

China Pharma  Holdings,  Inc.  develops,  manufactures,  and markets generic and
brand  bio-pharmaceutical   products  in  China  that  treat  a  wide  range  of
conditions, including infections,  hepatitis, vascular, CNS and other prevailing
diseases.   Helpson   Bio-pharmaceutical   Co.,  Ltd   (Helpson),   a  specialty
bio-pharmaceutical  company  headquartered  in Haikou City,  Hainan  province in
China, is a wholly owned subsidiary of China Pharma Holdings, Inc.

Safe Harbor  Statement  Under the Private  Securities  Litigation  Reform Act of
1995:  Any  statements  set  forth  above  that  are not  historical  facts  are
forward-looking statements that involve risks and uncertainties that could cause
actual  results  to  differ   materially  from  those  in  the   forward-looking
statements,  which  may  include,  but are  not  limited  to,  such  factors  as
unanticipated  changes  in product  demand,  increased  competition,  failure to
obtain or maintain  intellectual  property protection,  downturns in the Chinese
economy,  uncompetitive  levels of research and  development,  failure to obtain
regulatory  approvals,  and other information  detailed from time to time in the
Company's  filings and future  filings  with the United  States  Securities  and
Exchange Commission.

                                       ###
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
